Characterizing Genetic Risk at Known Prostate Cancer Susceptibility Loci in African Americans
Open Access
- 26 May 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Genetics
- Vol. 7 (5), e1001387
- https://doi.org/10.1371/journal.pgen.1001387
Abstract
GWAS of prostate cancer have been remarkably successful in revealing common genetic variants and novel biological pathways that are linked with its etiology. A more complete understanding of inherited susceptibility to prostate cancer in the general population will come from continuing such discovery efforts and from testing known risk alleles in diverse racial and ethnic groups. In this large study of prostate cancer in African American men (3,425 prostate cancer cases and 3,290 controls), we tested 49 risk variants located in 28 genomic regions identified through GWAS in men of European and Asian descent, and we replicated associations (at p≤0.05) with roughly half of these markers. Through fine-mapping, we identified nearby markers in many regions that better define associations in African Americans. At 8q24, we found 9 variants (p≤6×10−4) that best capture risk of prostate cancer in African Americans, many of which are more common in men of African than European descent. The markers found to be associated with risk at each locus improved risk modeling in African Americans (per allele OR = 1.17) over the alleles reported in the original GWAS (OR = 1.08). In summary, in this detailed analysis of the prostate cancer risk loci reported from GWAS, we have validated and improved upon markers of risk in some regions that better define the association with prostate cancer in African Americans. Our findings with variants at 8q24 also reinforce the importance of this region as a major risk locus for prostate cancer in men of African ancestry. Prostate cancer is one of the most common cancers in men and is especially frequent in men of African origin, as incidence rates in African Americans in the United States are >1.5–fold greater than rates in European Americans. In order to gain a more complete understanding of the genetic basis of inherited susceptibility to prostate cancer in men of African origin, we examined the associations at risk loci identified in men of European and Asian descent in a large African American sample of 3,425 cases of prostate cancer and 3,290 male controls. In testing 49 known risk variants, we were able to demonstrate that at least half of these variants also contribute to risk in African American men. We were able to find additional risk variants in many of the previously reported regions that better captured the pattern of risk in African American men. In addition, we verified and improved upon the evidence we previously reported that there are multiple risk variants in a region of 8q24 that are important in men of African origin.This publication has 45 references indexed in Scilit:
- A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24Nature Genetics, 2010
- Evidence for two independent prostate cancer risk–associated loci in the HNF1B gene at 17q12Nature Genetics, 2008
- Multiple loci identified in a genome-wide association study of prostate cancerNature Genetics, 2008
- Genome-wide association study identifies novel breast cancer susceptibility lociNature, 2007
- Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24Nature Genetics, 2007
- Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American menProceedings of the National Academy of Sciences of the United States of America, 2006
- Nonsteroidal Antiinflammatory Drugs and Decreased Risk of Advanced Prostate Cancer: Modification by Lymphotoxin AlphaAmerican Journal of Epidemiology, 2006
- Principal components analysis corrects for stratification in genome-wide association studiesNature Genetics, 2006
- A common variant associated with prostate cancer in European and African populationsNature Genetics, 2006
- The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and statusControlled Clinical Trials, 2000